

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

**I. RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR
II. PROPOSED APPOINTMENT OF
NEW INDEPENDENT NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of RemeGen Co., Ltd.* (the “**Company**”) hereby announces that a meeting of the Board was held on April 12, 2022 for the purposes of approving, among other things, the following resolutions.

I. RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR, MEMBER OF THE AUDIT COMMITTEE AND CHAIRPERSON OF THE REMUNERATION AND APPRAISAL COMMITTEE

Ms. Yu Shanshan (于珊珊) resigned the office as an independent non-executive Director, a member of the audit committee and the chairperson of the remuneration and appraisal committee of the Company due to personal work changes, and her resignation shall become effective until a new independent non-executive Director is elected to fill the vacancy.

Ms. Yu has confirmed that she has no disagreement with the Board and there is no other matter in relation to her resignation that needs to be brought to the attention of the shareholders of the Company. The Board would like to express its sincere gratitude to Ms. Yu for her contribution to the Company during her tenure of office.

II. PROPOSED APPOINTMENT OF NEW INDEPENDENT NON-EXECUTIVE DIRECTOR, MEMBER OF THE AUDIT COMMITTEE AND CHAIRPERSON OF THE REMUNERATION AND APPRAISAL COMMITTEE

The Board announces that Mr. Chen Yunjin (陳雲金) has been nominated as a candidate of the independent non-executive Director of the Company, which shall be subject to the consideration and approval at the extraordinary general meeting (the “EGM”) of the Company to be held on Thursday, May 5, 2022. If the proposed appointment has been approved, the term of office of Mr. Chen will be effective from the date of the EGM until the expiry of the term of the first session of the Board. At the expiry of such term of office, the term is renewable upon re-election.

The Board further announces that Mr. Chen has also been nominated as a member of the audit committee and the chairperson of the remuneration and appraisal committee, subject to the approval of his appointment as an independent non-executive Director at the EGM until the expiry of the term of the first session of the Board.

The biographical details of Mr. Chen are set out below:

Mr. Chen Yunjin, aged 36, graduated from Huaqiao University (華僑大學) in the PRC and obtained a bachelor’s degree in law in June 2009. Mr. Chen graduated from the Chinese University of Hong Kong in Hong Kong and obtained a master degree in common law in December 2010. Mr. Chen obtained the legal professional qualification in March 2010 and the lawyer qualification from the Department of Justice of the PRC in October 2012. Mr. Chen further obtained the qualification of fund practitioner from the Asset Management Association of China (中國證券投資基金業協會) in June 2021. Mr. Chen has been the executive director of Hold Cheng International Co., Ltd. (合成國際有限公司) since August 2020. He has been an executive director and the chief legal officer of Dao Sheng International Financial Leasing Co., Ltd. (道生國際融資租賃股份有限公司) since September 2015. Mr. Chen served as a legal officer of Chevalier International Holdings Limited (香港其士國際集團有限公司), a company listed on the Stock Exchange (stock code: 25), from July 2015 to December 2016. He served as the legal officer of SOCAM Development Limited (香港瑞安建業有限公司), a company listed on the Stock Exchange (stock code: 983), from January 2014 to June 2015. He served as the legal director (法務主任) of Korea Samsung Electronics (HK) Limited (韓國三星電子(香港)國際有限公司) from April 2012 to January 2014. He had also been a lawyer in Hunan Renhe (Zhuhai) Law Firm (湖南人和(珠海)律師事務所) from October 2012 to January 2014. He had also worked at the Hong Kong office of Gibson Dunn & Crutcher from August 2010 to April 2012.

In addition, the Company will consider the following resolution at the EGM:

Subject to the approval by the shareholders of the Company of his appointment, the Company will enter into a service contract with Mr. Chen and his term of office shall be effective from the date of the consideration and approval at the EGM and end on the expiry of the term of the first session of the Board. At the expiry of such term of office, the term is renewable upon re-election. The proposed remunerations scheme is follows: the fixed remuneration shall be RMB300,000 per year (tax inclusive).

Save as disclosed above, Mr. Chen confirmed that (i) he did not hold any position within the Group or any directorship of other listed public companies in the last three years; (ii) he does not have any relationship with any Director, supervisor, senior management, substantial or controlling shareholder of the Company; and (iii) he does not have any interest in the Shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong).

Save as disclosed above, the Company considers that there is no information which is disclosable nor is/was Mr. Chen involved in any of the matters required to be disclosed pursuant to the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there is no other matter that needs to be brought to the attention of the shareholders of the Company.

Mr. Chen has confirmed that he meets the independence criteria as set out in Rule 3.13 of the Listing Rules.

EGM

The EGM of the Company will be held on Thursday, May 5, 2022 for the purpose of considering the resolution in relation to the appointment of Mr. Chen Yunjin as an independent non-executive Director. The Company will despatch the notice of meeting of the EGM to the shareholders in due course.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive director

Yantai, the People's Republic of China
April 12, 2022

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Ms. Yu Shanshan, Mr. Hao Xianjing and Dr. Ma Lan as the independent non-executive directors.

* For identification purpose only